The EPS beat and positive clinical data are likely to drive near-term upside. The key catalyst is the Phase 2 proof-of-concept data for BGE-102 in cardiovascular risk, expected by year-end 2026. Monitor initiation of trials in mid-2026 and any partnership updates.
BIOA drugs
BIOA drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 8 $17.99entry
- T+1 · 6mo ago +0.94%α +0.71% · $18.16
- T+5 · 6mo ago +4.03%α +2.57% · $18.72
- T+20 · 5mo ago −12.73%α −12.75% · $15.70
- T+60 · 3mo ago −37.74%α −42.58% · $11.20
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioAge Labs reported Q1 2026 collaboration revenue of $2.8M (up from $1.5M YoY) and an EPS beat of $-0.52 vs consensus $-0.71 (26.8% beat). Net loss widened to $22.3M from $12.9M, driven by increased R&D spending on BGE-102 and APJ programs. The company highlighted positive Phase 1 data for BGE-102 and plans to initiate Phase 2 trials in mid-2026, with a strong cash position of $384.9M.
Key Financial Metrics
Key Facts
- Collaboration revenue of $2.8 million in Q1 2026 vs $1.5 million in Q1 2025
- Net loss of $22.3 million ($0.52 per share) vs consensus estimates of $-0.71 per share
- Positive topline Phase 1 data for BGE-102 (oral NLRP3 inhibitor) showing 86% median hsCRP reduction
- Phase 2 dose-ranging trial in cardiovascular risk planned for mid-2026, data expected by year-end
- Phase 1b/2a trial in diabetic macular edema also planned for mid-2026
- Cash, cash equivalents, and marketable securities of $384.9 million, sufficient through 2029
Financial Impact
Net loss per share beat consensus by 26.8% ($-0.52 vs $-0.71); collaboration revenue more than doubled YoY to $2.8M
Risk Factors
- Clinical trial failure or delays for BGE-102
- Rising operating losses and cash burn
- No approved products or recurring revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-213472 |
| Document: bioa-20260508.htm | 0001193125-26-213472 |
| Document: 0001193125-26-213472-index-headers.html | 0001193125-26-213472 |
| Document: 0001193125-26-213472-index.html | 0001193125-26-213472 |
| Document: 0001193125-26-213472.txt | 0001193125-26-213472 |
| 8-K Data (Synthetic) | 0001193125-26-213472 |
Track record
11 reports on BIOA
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +13.00% at T+60 after the Apr 21, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $5.50 Now $5.22 −5.09% settles Nov 23
- Nov 5, 202611d ago 8-K Neutral 4/10 No price data
- Nov 5, 202611d ago Press Release Neutral 4/10 Entry $5.34 to $5.55 Now $5.22 −2.25% ▲ +3.93% +1.34% vs SPY
- Jun 16, 202621w ago Press Release Neutral 3/10 Entry $20.49 to $22.32 Now $5.22 −74.52% ▲ +8.93% +11.16% vs SPY
- May 8, 202627w ago 8-K Bullish 7/10 Viewing Entry $17.99 to $18.72 Now $5.22 −70.98% ▲ +4.03% +2.57% vs SPY
- Apr 21, 202629w ago DEFA14A Neutral 3/10 Entry $18.36 to $17.14 Now $5.22 −71.57% ▼ −6.64% −6.70% vs SPY
- Apr 21, 202629w ago Press Release Bullish 8/10 Entry $19.61 to $17.44 Now $5.22 −73.38% ▼ −11.07% −12.15% vs SPY
- Apr 1, 202632w ago 144 Neutral 3/10 Entry $17.73 to $17.79 Now $5.22 −70.56% ▲ +0.34% −3.43% vs SPY
- Mar 24, 202633w ago Press Release Mixed 6/10 Entry $16.11 to $17.49 Now $5.22 −67.60% ▲ +8.57% +8.99% vs SPY
- Mar 2, 202637w ago Court Ruling Bullish 7/10 Entry $20.46 to $20.97 Now $5.22 −74.49% ▲ +2.49% +2.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers